Goal is to use AutovaxID to produce patient-specific cells for tissue and organ repair.
The U.S. Federal Government approved $1.6 million in biomedical research funds for the Defense Department’s Cancer Immunotherapy and Cell Therapy Initiative, which is intended to support research into new applications for Biovest’s cell-manufacturing device. The aim is to use AutovaxID™ to cost-effectively and efficiently manufacture difficult-to-produce therapeutic proteins and personalized vaccines.
“With this expected critical funding support, we intend to further develop AutovaxID to be capable of growing patient-specific cells that could be used to rebuild damaged tissue or organs,” says chairman and CEO, Steven Arikian, M.D. “The potential applications following trauma or injury are numerous, such as for the production of autologous skin for burn repair, growth of bone for fracture repair, and/or the production of tissue for plastic reconstruction of severe injuries.”
AutovaxID is an automated single-use, closed-system disposable bioreactor. It is currently use to manufacture Biovest’s personalized anticancer vaccine, BiovaxID®, which targets B-cell blood cancers such as non-Hodgkin’s lymphoma.
